4.4 Article

Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement

Journal

REGULATORY TOXICOLOGY AND PHARMACOLOGY
Volume 81, Issue -, Pages 489-499

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yrtph.2016.09.014

Keywords

Reduced risk product; Modified risk tobacco product; Tobacco heating system; Smoking; Smoking abstinence; Harmful and potentially harmful constituents; Biomarkers of exposure; Randomized study

Funding

  1. Philip Morris Products S.A.

Ask authors/readers for more resources

Smoking conventional cigarettes (CCs) exposes smokers to harmful and potentially harmful constituents (HPHCs). The Tobacco Heating System 2.2 (THS 2.2), a candidate modified risk tobacco product, was developed to reduce or eliminate the formation of HPHCs, while preserving as much as possible the taste, sensory experience, nicotine delivery profile and ritual characteristics of CC. This randomized, controlled, open-label study in confinement for 5 day exposure aimed to demonstrate the reduction in exposure to selected HPHCs, to assess nicotine uptake and subjective effects, in participants switching to THS 2.2 (n = 80) compared to participants continuing smoking CCs (n = 40) and abstaining from smoking (n = 40). The subjects were randomized according to sex and daily CC consumption. The levels of biomarkers of exposure to HPHCs were significantly reduced in participants switching to THS 2.2, compared to CC use. More importantly, the magnitude of exposure reduction observed was close to that which was seen in participants who abstained from smoking for 5 days, while nicotine uptake was maintained. Reduction in urge-to-smoke was comparable between THS and CC groups, however THS 2.2 was slightly less satisfactory than CCs. The new, alternative tobacco product THS 2.2 was well tolerated. (C) 2016 Philip Morris Products S.A. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease

Emily Chan, Eunice L. Kwak, Jimmy Hwang, Marja Heiskala, Guillaume de La Bourdonnaye, Monica Mita

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)

Article Medicine, Legal

Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland

Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Ludicke

REGULATORY TOXICOLOGY AND PHARMACOLOGY (2016)

Article Oncology

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

David A. Smith, Paul Conkling, Donald A. Richards, John J. Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice S. Bexon

CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)

Article Toxicology

Influence of smoking on levels of urinary 8-iso Prostaglandin F2α

Angela van der Plas, Sandrine Pouly, Guillaume de La Bourdonnaye, Gizelle Baker, Frank Luedicke

TOXICOLOGY REPORTS (2019)

Article Multidisciplinary Sciences

Biomarker of exposure level data set in smokers switching from conventional cigarettes to Tobacco Heating System 2.2, continuing smoking or abstaining from smoking for 5 days

Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Ludicke

DATA IN BRIEF (2017)

Review Toxicology

Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B-2

Angela van der Plas, Sandrine Pouly, Guillaume de la Bourdonnaye, Wee Teck Ng, Gizelle Baker, Frank Ludicke

TOXICOLOGY REPORTS (2018)

Article Medicine, Legal

New supporting data to guide the use of evident toxicity in acute oral toxicity studies (OECD TG 420)

Fiona Sewell, Ian Ragan, Graham Horgan, David Andrew, Thomas Holmes, Irene Manou, Boris P. Mueller, Tim Rowan, Barbara G. Schmitt, Marco Corvaro

Summary: There are currently three test guidelines for acute oral toxicity studies, but the subjectivity of one guideline may be hindering its wider use. In order to address this, the NC3Rs and EPAA collaborated to analyze historical data and provide recommendations on the recognition of 'evident toxicity'.

REGULATORY TOXICOLOGY AND PHARMACOLOGY (2024)

Article Medicine, Legal

The 2022 world health organization reevaluation of human and mammalian toxic equivalency factors for polychlorinated dioxins, dibenzofurans and biphenyls

Michael DeVito, Bas Bokkers, Majorie B. M. van Duursen, Karin van Ede, Mark Feeley, Elsa Antunes Fernandes Gaspar, Laurie Haws, Sean Kennedy, Richard E. Peterson, Ron Hoogenboom, Keiko Nohara, Kim Petersen, Cynthia Rider, Martin Rose, Stephen Safe, Dieter Schrenk, Matthew W. Wheeler, Daniele S. Wikoff, Bin Zhao, Martin van den Berg

Summary: In October 2022, the World Health Organization reevaluated the toxic equivalency factors (TEFs) for chlorinated dioxin-like compounds in a panel convened in Lisbon. This effort utilized an updated database, Bayesian dose response modeling, and meta-analysis to derive Best-Estimate TEFs. Applying these new TEFs may result in lower total toxic equivalents for dioxin-like chemicals.

REGULATORY TOXICOLOGY AND PHARMACOLOGY (2024)